Clinical Trials
22 trialsNCT06433219 2026-06-03
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono
Phase 2 Active not recruiting
NCT05010031 2026-05-11
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07522697 2026-04-13
MITO END-4
National Cancer Institute, Naples
Phase 2 Not yet recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
NCT06463028 2025-12-24
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Faeth Therapeutics
Phase 2 Recruiting
NCT04564027 2025-08-29
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
AstraZeneca
Phase 2 Completed
NCT04038502 2025-08-20
COBRA
VA Office of Research and Development
Phase 2 Recruiting
NCT03126019 2025-03-14
CITADEL-203
Incyte Corporation
Phase 2 Completed
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT04768296 2024-09-26
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
Phase 2 Completed
NCT05103358 2024-06-03
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc.
Phase 2 Unknown
NCT02718300 2024-05-01
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Incyte Corporation
Phase 2 Terminated
NCT04163419 2024-03-13
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Massachusetts General Hospital
Phase 2 Unknown
NCT01320085 2024-01-24
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Pfizer
Phase 2 Completed
NCT03565991 2023-09-25
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Pfizer
Phase 2 Terminated
NCT03386162 2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2 Terminated
NCT01276379 2021-07-02
POSIBA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT01942993 2020-09-30
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01640444 2019-04-11
VISNU-2
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT02644122 2018-07-11
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
University of California, San Diego
Phase 2 Terminated